

ANIKA THERAPEUTICS INC
Form 8-K
July 27, 2004

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **July 26, 2004**

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Massachusetts
(State or Other Jurisdiction of
Incorporation)

000-21326
(Commission File
Number)

04-3145961
(I.R.S. Employer Identification No.)

160 New Boston Street, Woburn, Massachusetts
(Address of Principal Executive Offices)

01801
(Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 932-6616**

Item 5: Other Events and Required FD Disclosure.

On July 26, 2004, Anika Therapeutics, Inc. issued a press release (Press Release) announcing the signing of an exclusive worldwide development and commercialization partnership with the Ortho Neutrogena Division of Ortho-McNeil Pharmaceutical, Inc., for its hyaluronic acid based cosmetic tissue augmentation therapy. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.

Item 7: Financial Statements, *Pro Forma* Financial Information and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1	Press Release issued by Anika Therapeutics, Inc. on July 26, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ANIKA THERAPEUTICS, INC.

July 26, 2004

By: /s/ William J. Knight
 William J. Knight
 Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Anika Therapeutics, Inc. dated July 26, 2004